Frontlight ResearchEarly access
Taking people in FrancePhase 3
A shorter BPaLM treatment for multidrug-resistant tuberculosis
Compares BPaLM with longer standard treatment in multidrug-resistant tuberculosis.
Key facts
- Who runs it
- Assistance Publique Hopitaux De Paris
- Where
- Amiens, Bordeaux, Briis-sous-Forges, Lyon Cedex 04, Montpellier Cedex 5, Nantes, Nice, Paris, Paris Cedex 18, Rennes, Schiltigheim, and Toulouse, FranceSee the 12 sites
- Trial code
- Registry title
- Feasibility of the Application of a new Six-month Treatment for multidrug-resistant tuberculosis (MDR-TB) patients in France (FAST-MDR)
- Status
- Recruiting
- Phase
- Phase 3
- People taking part
- 50 people, planned
- Started
- 11 Sept 2026
- Expected to end
- 2 Jun 2029
- Type of study
- Interventional
- Record updated
- 31 July 2025
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults with tuberculosis that is resistant to rifampicin, confirmed by lab tests. It tests a new six-month treatment called BPaLM.
- Age
- 18 years or older
- Sex
- All sexes can join.
- Disease stage
- Tuberculosis confirmed by bacteria or molecular tests, caused by strains resistant to rifampicin (with or without isoniazid resistance), shown by a rapid molecular test.
- Earlier treatment
- Cannot join if exposed for 30 days or more in the past five years to bedaquiline, clofazimine, delamanid, linezolid or pretomanid. Cannot join if already on a treatment for MDR/RR-TB for 4 weeks or more with no need to change it.
- Biomarker or test result
- Resistance to rifampicin shown by a rapid molecular test.
Main reasons for not taking part
- Unable to take oral drugs
- Proven or likely resistance to bedaquiline, clofazimine, linezolid, pretomanid or moxifloxacine
- Severe TB outside the lungs, such as meningo-encephalitis, brain abscess, osteo-arthritis or osteomyelitis
- QTcF interval of 500 msec or more on any ECG, or any cardiac risk factor for severe arrhythmia
- Known to be pregnant, or unwilling or unable to stop breastfeeding
The registry criteria, word for word
Show all 18 criteriaShow less
Who can take part
- Is 18 years old or more
- Is affected by bacteriologically- or molecularly-confirmed tuberculosis, due to strains of M. tuberculosis resistant to rifampicin (with or without resistance to isoniazid) according to a rapid molecular test
- Is willing and able to give informed consent to be enrolled in the research project (signed or witnessed consent if the patient is illiterate)
- Is willing to use effective contraception: women with childbearing potential must agree to use effective contraception, unless their partner has had a vasectomy, for the duration of study treatment and up to 6 months after the end of study treatment; men who have not had a vasectomy must agree to use effective contraception for the duration of study treatment and up to 3 months after the end of study treatment
- Is affiliated to a social security system (as beneficiary) or has state medical aid (AME) or has an ongoing demand for AME or has an ongoing demand for an emergency medical care (dispositif de soins d'urgence, as applicable for tuberculosis)
Who cannot take part
- Is unable to take oral drugs
- Is taking or needs to take contraindicated medications in association with investigational medicinal products
- Has any other condition (social or medical) which, in the opinion of the site investigator, would make the study participant unsafe
- Has known allergies, hypersensitivity or intolerance or any other medical condition and contra indications to any drug of the regimen
- Has ≥500 msec QTcF interval on any ECG taken at screening or baseline visits, or has any cardiac risk factor for severe arrhythmia
- Is already on a MDR/RR-TB treatment regimen since 4 weeks or more, and has no need to change the treatment regimen (i.e. adverse events, treatment failure)
- Has significant and uncorrectable lab abnormalities at baseline: haemoglobin ≤7.9 g/dL, platelet count <75 000/mm3; absolute neutrophil count <1 000/ mm3; potassium <3.0 mEq/L; serum creatinine >3 x upper level of normality (ULN); alanine aminotransferase (ALT) ≥3 x ULN
- Has peripheral neuropathy of grade 3 or 4 (CTCAE scale)
- Is known to be pregnant or is unwilling or unable to stop breastfeeding an infant
- Unwilling to comply to study procedures, at the clinician appreciation
- Has proven or likely resistance to bedaquiline, clofazimine, linezolid, pretomanid or moxifloxacine, or has had exposure (for 30 days or more) in past five years to bedaquiline, clofazimine, delamanid, linezolid, or pretomanid
- Has severe extrapulmonary TB, including meningo-encephalitis, brain abscess, osteo-arthritis, osteomyelitis
- Is concurrently participating in another trial of any medicinal product
Where in France
- Centre Hospitalier Universitaire Amiens - PicardieAmiens, FranceTaking people
- Centre hospitalier Universitaire de BordeauxBordeaux, FranceTaking people
- Centre hospitalier de BlignyBriis-sous-Forges, FranceTaking people
- Hospices Civils De LyonLyon Cedex 04, FranceTaking people
- Centre Hospitalier Universitaire De MontpellierMontpellier Cedex 5, FranceTaking people
- Centre Hospitalier Universitaire de NantesNantes, FranceTaking people
- Centre Hospitalier Universitaire de NiceNice, FranceTaking people
- Assistance Publique Hopitaux de ParisParis, FranceTaking people
- Assistance Publique Hopitaux De ParisParis Cedex 18, FranceTaking people
- Centre Hospitalier Universitaire de RennesRennes, FranceTaking people
- Les Hopitaux Universitaires De StrasbourgSchiltigheim, FranceTaking people
- Centre Hospitalier Universitaire de ToulouseToulouse, FranceTaking people
About the trial
What the trial wants to find out
Determine if BPaLM has non-inferior effectiveness at 18 months after study treatment start compared to the long, conventional MDR-TB regimens assessed in an historical cohort of patients treated in France in 2006-2022.
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record
Print a page for my doctorData and sources
- Registry record
- Listed on the EU's official list of trials (CTIS).
- Official title
- Feasibility of the Application of a new Six-month Treatment for multidrug-resistant tuberculosis (MDR-TB) patients in France (FAST-MDR)
- Plain-language title
- A shorter BPaLM treatment for multidrug-resistant tuberculosisGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 9 November 2026.
- Record updated
- 31 July 2025